GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » Operating Income

Grand Pharmaceutical Group (HKSE:00512) Operating Income : HK$2,823 Mil (TTM As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group Operating Income?

Grand Pharmaceutical Group's Operating Income for the six months ended in Dec. 2023 was HK$1,288 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,823 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Grand Pharmaceutical Group's Operating Income for the six months ended in Dec. 2023 was HK$1,288 Mil. Grand Pharmaceutical Group's Revenue for the six months ended in Dec. 2023 was HK$4,540 Mil. Therefore, Grand Pharmaceutical Group's Operating Margin % for the quarter that ended in Dec. 2023 was 28.38%.

Good Sign:

Grand Pharmaceutical Group Ltd operating margin is expanding. Margin expansion is usually a good sign.

Grand Pharmaceutical Group's 5-Year average Growth Rate for Operating Margin % was 9.80% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Grand Pharmaceutical Group's annualized ROC % for the quarter that ended in Dec. 2023 was 10.62%. Grand Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 54.67%.


Grand Pharmaceutical Group Operating Income Historical Data

The historical data trend for Grand Pharmaceutical Group's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group Operating Income Chart

Grand Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,399.41 1,768.65 2,014.90 2,683.19 2,823.29

Grand Pharmaceutical Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 966.00 1,336.21 1,346.98 1,534.87 1,288.42

Grand Pharmaceutical Group Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2,823 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grand Pharmaceutical Group  (HKSE:00512) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Grand Pharmaceutical Group's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=2576.842 * ( 1 - 17.66% )/( (20548.82 + 19399.231)/ 2 )
=2121.7717028/19974.0255
=10.62 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=22449.207 - 1395.013 - ( 2196.135 - max(0, 6495.276 - 7000.65+2196.135))
=20548.82

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=22515.326 - 1831.387 - ( 2474.298 - max(0, 5731.437 - 7016.145+2474.298))
=19399.231

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Grand Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2220.824/( ( (3823.573 + max(679.157, 0)) + (3621.014 + max(-129.095, 0)) )/ 2 )
=2220.824/( ( 4502.73 + 3621.014 )/ 2 )
=2220.824/4061.872
=54.67 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2078.413 + 1107.562 + 685.257) - (1395.013 + 0 + 1797.062)
=679.157

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(958.261 + 1388.649 + 902.835) - (1831.387 + 0 + 1547.453)
=-129.095

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Grand Pharmaceutical Group's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=1288.421/4540.104
=28.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Grand Pharmaceutical Group Operating Income Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Grand Pharmaceutical Group (HKSE:00512) Business Description

Traded in Other Exchanges
Address
99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.
Executives
Shang Hai Yuan Da Chan Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Hu Kaijun 2201 Interest of corporation controlled by you
East Ocean Capital (hong Kong) Company Limited 2101 Beneficial owner
Lion River I N.v. 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd. 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Citic Group Corporation 2201 Interest of corporation controlled by you
Citic Limited 2201 Interest of corporation controlled by you
China Citic Bank Corporation Limited 2201 Interest of corporation controlled by you
Cncb (hong Kong) Investment Limited 2106 Person having a security interest in shares
Grand (hongkong) International Investments Holdings Limited
Chau Tung
Zhong Guo Yuan Da Ji Tuan You Xian Ze Ren Gong Si
Outwit Investments Limited

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines